MergerJul 24, 2026, 12:21 PM
Lisata Therapeutics Merger Agreement Terminated; $2M Fee Due
AI Summary
Lisata Therapeutics, Inc. announced the termination of its Agreement and Plan of Merger with Kuva Labs Inc. and Kuva Acquisition Corp. on July 24, 2026. The termination occurred because the Parent and Purchaser failed to secure sufficient financing to fund the tender offer. As a result, Lisata Therapeutics is entitled to a $2,000,000 termination fee and reserves all rights to seek further legal remedies. The company's Board of Directors will now assess strategic options to enhance stockholder value, which may include a reverse merger, asset sales, or dissolution.
Key Highlights
- Merger Agreement with Kuva Labs Inc. and Kuva Acquisition Corp. terminated on July 24, 2026.
- Termination due to Parent and Purchaser's failure to obtain sufficient financing for the Offer.
- Original offer price was $4.00 per Common Share plus one CVR for up to $3.00.
- Lisata Therapeutics is owed a $2,000,000 termination fee from Parent.
- Company reserves rights to seek additional legal remedies, including for Willful Breach.
- Board of Directors plans to assess strategic options, including reverse merger, asset sales, or dissolution.
Price Impact
More from LSTA